GnRH antagonists in in vitro fertilization: Were we are now

Minerva Ginecologica

Volumn 55, Issue 5, 2003, Pages 373-388

  Shapiro, D B ^a   Mitchell Leef, D ^a  

^a REPRODUCTIVE BIOLOGY ASSOCIATES   (United States)

Author keywords

Fertilization in vitro; Gonadorelin, antagonists; Infertility

Indexed keywords

ANTIESTROGEN; BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; GANIRELIX; GESTAGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN; DRUG DERIVATIVE; GONADORELIN;

ADD BACK THERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG RECEPTOR BINDING; DRUG SAFETY; FEMALE; FERTILIZATION IN VITRO; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; INFERTILITY; INJECTION; META ANALYSIS; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; REVIEW; DRUG ANTAGONISM; METHODOLOGY; PHYSIOLOGY;

CLINICAL TRIALS; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION;

EID: 0347995072     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Porter RN, Smith W, Craft IL, Ardulwahib NA, Jacobs HS. Induction of ovulation for in vitro fertilization using buserelin and gonadotropins. Lancet 1984;2:1284-5.
2. Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt K, Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab 1992;75:393-8.
3. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ et al. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45.
4. Albano C, Felberbaum RE, Smitz J, Riethmueller-Winzen H, Engel J, Diedrich K et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000;15:526-31.
5. The European Orgalutran Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-8.
6. The European Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644-51.
7. Felberbaum RE, Albano C, Ludwig M, Riethmüller-Winzen H, Grigat M, Devroey P et al. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist Cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15:1015-20.
8. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud, Alvarez S, Moreau L et al. Prospective, randomized, controlled study of IVF-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triplorelin). Fertil Steril 2000;73:314-20.
9. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;17:874-85.
10. Ludwig M, Katalinic A, Banz C, Schröder AK, Löning M, Weiss JM et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002;17:2842-5.
11. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003;88:166-73.
12. Shapiro DB. Real-life clinical applications of GnRH antagonists: individualization of fertility treatment. Fertil Steril 2003;80:S8-S15.
13. Obelye JJL, Mannaerts BMJL, Huisman JAM, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999;72:1006-12.
14. Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003;79:873-80.
15. De Placido G, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod 2001;16:1875-9.
16. Copperman AB. Real-life clinical applications of GnRH antagonists: individualization of fertility treatment. Fertil Steril 2003;80:S16-S24.
17. th Annual Meeting of the ESHRE, June 30-July 3, 2002, Vienna, Austria 2002.
18. Fanchin R, Cunha-Filho JS, Schonäuer LM, Kadoch IJ, Cohen-Bacri P, Frydman R. Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens. Fertil Steril 2003;79:316-21.
19. Doody KJ, Langley M, Marek D, Doody K. Oral contraceptive pre-treatment for IVF cycles employing recombinant FSH and a GnRH antagonist. Fertil Steril 2001;76(3 Suppl 1):S236.
20. Meldrum DR. Vascular endothelial growth factor, polycystic ovary syndrome, and ovarian hyperstimulation syndrome. Fertil Steril 2002;78:1170-1.
21. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update 1996;6:483-506.
22. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-5.
23. Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Hum Reprod 2002;17:2230-6.
24. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002;17:2858-64.
25. Cataldo NA, Abbasi F, McLaughlin TL, Lamendola C, Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertil Steril 2001;76:1057-9.
26. Elkind-Hirscb KE, Webster BW, Brown CP, Vemon MW. Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003;79:603-7.
27. Cardone VS. Real-life clinical applications of GnRH antagonists: individualization of fertility treatment. Fertil Steril 2003;80:S25-S31.
28. Schenker JG, Ezra Y. Complications of assisted reproductive techniques Fertil Steril 1994;61:411-22.
29. MacDougall MJ, Tan SL, Jacobs HS. In vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992;7:597-600.
30. Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmuller-Winzen H, Schuler A et al. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 2000;264:29-32.
31. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001;265:175-82.
32. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metod 2002;87:709-15.
33. Bracero NJ, Jurema MW, Posada MN, Whelan JG, Garcia JE, Vlahos NP. Triggering ovulation with leuprolide acetate (LA) instead of human chorionic gonadotropin (hCG) after the use of ganirelix for in vitro fertilization-embryo transfer (IVF-ET) does not compromise cycle outcome and may prevent ovarian hyperstimulation syndrome. Fertil Steril 2001;76 Suppl:S93.
34. Williams SC, Gibbons WE, Muasher SJ, Oehninger S. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril 2002;78:1068-72.
35. Rongières-Bertrand C, Olivennes F, Righini C, Fanchin R, Taïeb J, Hamamah S et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999;14:683-8.
36. Penzias AS. Luteal phase support. Fertil Steril 2002;77:318-23.
37. th Annual Meeting of the ESHRE, June 30-July 3, 2002.